Replacement - NIH Licensing Agreeme

This announcement replaces the announcement made on 11 May 2010 and contains
changes to the definitions of the relevant parties.

                             Scancell Holdings Plc                             

                                 (`Scancell')                                  

               National Institutes of Health Licensing Agreement               

Scancell Holdings Plc, (PLUS:SCLP), the developer of therapeutic cancer
vaccines, is pleased to announce it has signed a worldwide non-exclusive
licensing agreement with the National Institutes of Health (`NIH'), an agency
of the United States Department of Health and Human Services, for use of the
melanoma antigens TRP-2 and gp100, developed in the laboratory of Steven A.
Rosenberg, M.D., Ph.D., at the National Cancer Institute. These antigens will
be utilized as key components of Scancell's lead ImmunoBody® vaccine for
melanoma, SCIB1.

Under the agreement, Scancell has agreed to pay the US Public Health Service an
undisclosed upfront fee in addition to certain milestone fees and a royalty on
future sales of SCIB1. Scancell will have the right to develop and
commercialise its ImmunoBody® vaccines for the treatment of melanoma in humans
incorporating epitopes from these targets.

ImmunoBody® vaccines generate the high-avidity T-cells that kill cancer cells,
which may overcome the current limitations of most cancer vaccines. Scancell is
expected to commence its Phase I clinical trials for SCIB1 in Q2 2010.

David Evans, chairman of Scancell, commented:

"This agreement strengthens Scancell's IP position around SCIB1 and enables the
Company to move forward towards its proposed clinical trials of the melanoma
vaccine."

                                    -ENDS-                                     

For Further Information:

David Evans, Chairman           Scancell Holdings Plc    + 44 774 008 4452   
                                                                             
Professor Lindy Durrant, CEO    Scancell Holdings Plc    + 44 207 245 1100   
                                                                             
Kirsty Corcoran/John Bick       Hansard Communications   + 44 207 245 1100   
                                                                             
Ross Andrews / Tom Rowley       Zeus Capital             + 44 161 831 1512   

About Scancell

Scancell is developing novel therapeutic vaccines for the treatment of cancer
and infectious diseases based on its groundbreaking ImmunoBody® technology
platform. Scancell's first cancer vaccine SCIB1 is being developed for the
treatment of melanoma and is expected to enter clinical trials in 2010.

Treating cancer by vaccination allows small non-toxic doses of a vaccine to be
administered to a patient, stimulating an immune response. Effective cancer
vaccines need to target dendritic cells to stimulate both parts of the cellular
immune system; the helper cell system where inflammation is stimulated at the
tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system
cells are primed to recognise and kill specific cells.

A limitation of many cancer vaccines currently in development is that they
cannot specifically target dendritic cells in vivo. Several groups have
demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing
them with tumour antigens and re-infusing them. However, this procedure is
patient specific, time consuming and expensive. Scancell has developed its
breakthrough patent protected ImmunoBody® technology to overcome these
limitations.

An ImmunoBody® is a human antibody or fusion protein engineered to express
helper cell and CTL epitopes from tumour antigens over-expressed by cancer
cells. Antibodies are ideal vectors for carrying T cell epitopes from tumour
antigens as they have long half-lives and can effectively target dendritic
cells via their Fc receptors, allowing efficient stimulation of both helper and
CTL responses.

The Immunobody® technology can be adapted to provide the basis for treating any
tumour type and may also be of potential utility in the development of vaccines
against hepatitis, HIV and other chronic infectious diseases.